BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32127619)

  • 1. Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma.
    Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Lei HJ; Su CW; Lee RC; Hou MC; Huo TI
    Sci Rep; 2020 Mar; 10(1):3925. PubMed ID: 32127619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.
    Hsu CY; Huang YH; Hsia CY; Su CW; Lin HC; Loong CC; Chiou YY; Chiang JH; Lee PC; Huo TI; Lee SD
    J Hepatol; 2010 Jul; 53(1):108-17. PubMed ID: 20451283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
    Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
    World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Apr; 27(4):690-9. PubMed ID: 22436058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma.
    Chan AW; Chong CC; Mo FK; Wong J; Yeo W; Johnson PJ; Yu S; Lai PB; Chan AT; To KF; Chan SL
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1766-1772. PubMed ID: 26992142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population.
    Urakawa H; Kora SI; Mitsufuji T; Osame A; Higahsihara H; Yoshimitsu K
    Acta Radiol; 2016 Dec; 57(12):1445-1452. PubMed ID: 26861204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluations of seven different clinical staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection].
    Zhao J; Yan T; Huang Z; Bi X; Zhao H; Zhou J; Li Z; Li Y; Li C; Cai J
    Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):903-7. PubMed ID: 24854909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
    Kudo M; Chung H; Osaki Y
    J Gastroenterol; 2003; 38(3):207-15. PubMed ID: 12673442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients.
    Abdelaziz AO; Shousha HI; Abdelmaksoud AH; Saad Y; Elbaz TM; Soliman ZA; Salah A; Lithy R; Ahmed M; Nabil MM
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):514-519. PubMed ID: 29465472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma.
    Mohsen W; Rodov M; Prakoso E; Charlton B; Bowen DG; Koorey DJ; Shackel NA; McCaughan GW; Strasser SI
    World J Gastroenterol; 2017 Apr; 23(15):2763-2770. PubMed ID: 28487614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
    Chen ZX; Jian ZW; Wu XW; Wang JC; Peng JY; Lao XM
    Cancer Med; 2019 Sep; 8(11):5097-5107. PubMed ID: 31313476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
    Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
    Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
    Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma.
    Hsu CY; Liu PH; Ho SY; Hsia CY; Kudaravalli P; Lee YH; Chiou YY; Tsai YJ; Huang YH; Huo TI
    BMC Cancer; 2018 Mar; 18(1):289. PubMed ID: 29540157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
    Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
    Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee PC; Loong CC; Chiang JH; Huo TI; Lee SD
    Cancer; 2010 Jun; 116(12):3006-14. PubMed ID: 20564406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience.
    Stefansdottir J; Christensen E; Schiødt FV
    Scand J Gastroenterol; 2017; 52(6-7):768-772. PubMed ID: 28355956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.